510(k) Report

510(k) · Cleared

Cleared

Nerivio

K201824510(k) TraditionalCleared Oct 23, 2020114-day reviewClass II21 CFR 882.5899

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Theranica Bio-Electronics, Ltd. · QGT Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine

Cleared on Oct 23, 2020 as substantially equivalent to DEN180059 (Theranica Bioelectronics, Ltd., 2019) after a 114-day review. Its family tree reaches back 1 generation to 2019. 5 later devices descend from it.

Decided
Oct 23, 2020
Review
114 days
Class
Class II
Product code
QGT
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to DEN180059 (2019). 5 later devices descend from it, 1 citing it directly.

Descendants, by year cleared 2021: 1 descendant cleared2023: 2 descendants cleared2024: 1 descendant cleared2025: 1 descendant clearedDEN180059 · Nerivio Migra · Theranica Bioelectronics, Ltd. · 2019201620182020202220242026
Descendants, by generation 1 generation forward: 1 descendant2 generations forward: 1 descendant3 generations forward: 2 descendants4 generations forward: 1 descendant DEN180059 · Nerivio Migra · Theranica Bioelectronics, Ltd. · 20190
  1. Root · 1 generation backDEN180059 Nerivio MigraTheranica Bioelectronics, Ltd. · 2019
  2. This deviceK201824 NerivioTheranica Bio-Electronics, Ltd. · 2020
  3. Descendant · cites it directly · 4 of its ownK203181 Nerivio, FGD000075-4.7Theranica Bioelectronics, Ltd. · 2021
  4. Descendant · 2 generations on · 3 of its ownK223169 NerivioTheranica Bioelectronics, Ltd. · 2023
  5. Descendant · 3 generations on · 2 of its ownK232152 NerivioInfinityTheranica Bioelectronics, Ltd. · 2023
  6. Descendant · 3 generations on · 1 of its ownK241756 Nerivio; NerivioInfinityTheranica Bio-Electronics, Ltd. · 2024
  7. Descendant · 4 generations on · 0 of its ownK250405 Nerivio; Nerivio InfinityTheranica Bio-Electronics, Ltd. · 2025 · Recalled

Most influential descendants

Showing 5 of 5 · See all
  • K203181Nerivio, FGD000075-4.7Theranica Bioelectronics, Ltd. · 2021 · cites it directly4descendants
  • K223169NerivioTheranica Bioelectronics, Ltd. · 2023 · 2 generations on3descendants
  • K232152NerivioInfinityTheranica Bioelectronics, Ltd. · 2023 · 3 generations on2descendants
  • K241756Nerivio; NerivioInfinityTheranica Bio-Electronics, Ltd. · 2024 · 3 generations on1descendant
  • K250405Nerivio; Nerivio InfinityTheranica Bio-Electronics, Ltd. · 2025 · 4 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN180059Nerivio MigraTheranica Bioelectronics, Ltd.2019—
0 (this device)K201824NerivioTheranica Bio-Electronics, Ltd.2020—
+1K203181Nerivio, FGD000075-4.7Theranica Bioelectronics, Ltd.2021—
+2K223169NerivioTheranica Bioelectronics, Ltd.2023—
+3K232152NerivioInfinityTheranica Bioelectronics, Ltd.2023—
+3K241756Nerivio; NerivioInfinityTheranica Bio-Electronics, Ltd.2024—
+4K250405Nerivio; Nerivio InfinityTheranica Bio-Electronics, Ltd.20251

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202110
202320
202410
202510
FIG. 1 — Lineage of K201824, 2019–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QGT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QGT device

  1. #1 K241756 Nerivio; NerivioInfinityscore 12.3 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN180059Nerivio Migra
Summary page 4
…ulatory Class: Class II Product Code: QGT Predicate Device: Device Name: Nerivio Migra Manufacturer: Theranica Bio-Electronics LTD. 510(K) Number: DEN180059 Device Description: The Nerivio is a wearable, battery-powered device that is controlled by a mobile application. The system del…
Theranica Bioelectronics, Ltd.2019—

What descends from it? (5)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K203181Nerivio, FGD000075-4.7Theranica Bioelectronics, Ltd.20214

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K203181 (Theranica Bioelectronics, Ltd., 2021) has gone furthest, with 4 descendants of its own.

How does its category compare?

All QGT devices

QGT Distal Transcutaneous Electrical Stimulator For Treatment Of Acute Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2020, this device’s year, is highlighted.

FDA decisions per year · QGT

1in 2025

2019: 12020: 12021: 12023: 22024: 12025: 1
2007high 2 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QGT

Too few QGT 510(k)s in any year since 2007 to give a median.

Recalls per year · QGT

1so far in 2026, the most since 2007

2026 (partial year): 1
2007high 1 (2026) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · QGT

3in 2022

2020: 12022: 3
2007high 3 (2022) · low 0 (2007)2025

MAUDE reports naming product code QGT, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20191—00
20201—01
20211—00
20220—03
20232—00
20241—00
20251—00
20260—1—

What is it indicated for?

The Nerivio is intended for acute treatment of migraine with or without aura in patients 18 years of age or older. It is a prescription use, self-administered device for use in the home environment at the onset of migraine headache or aura.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K201824: Nerivio.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K201824

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026